Stevanato Group Spa (NYSE:STVN) has received a consensus rating of “Buy” from the nine brokerages that currently cover the company, Marketbeat reports. One analyst rated the stock with a hold rating and eight gave the company a buy rating. The 12-month average price target among brokers who have reported on the stock over the past year is €26.56 ($29.85).
Separately, Zacks Investment Research upgraded Stevanato Group shares from a “hold” rating to a “buy” rating and set a target price of $19.00 on the stock in a Wednesday, January 12 research report. .
NYSE:STVN shares opened at €17.37 ($19.52) on Tuesday. The company has a 50-day simple moving average of €20.89. Stevanato Group has a one-year minimum of €15.20 ($17.08) and a one-year maximum of €29.18 ($32.79). The company has a debt ratio of 0.30, a current ratio of 2.66 and a quick ratio of 2.21.
Stevanato Group Inc (NYSE:STVN) last released its quarterly results on Tuesday, November 9. The company reported earnings per share (EPS) of €0.10 ($0.11) for the quarter, missing the consensus estimate of €0.46 ($0.52) by (€0.36) ( ($0.40)). The company posted revenue of 214.50 million euros for the quarter, against analysts’ expectations of 211.79 million euros. As a group, sell-side analysts expect Stevanato Group to post EPS of 0.52 for the current year.
A number of large investors have recently bought and sold shares of the company. UBS Group AG bought a new position in Stevanato Group shares in Q3 worth $55,000. Captrust Financial Advisors bought a new position in Stevanato Group shares in Q3 worth $56,000. Russell Investments Group Ltd. bought a new position in Stevanato Group shares in Q4 worth $93,000. Advisor Group Holdings Inc. bought a new position in Stevanato Group stock in Q3 worth $176,000. Finally, Parallel Advisors LLC bought a new position in Stevanato Group shares in Q4 worth $186,000. 11.26% of the shares are currently held by institutional investors.
About the Stevanato Group
Stevanato Group SpA is a provider of containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life science industries. Stevanato Group SpA is based in PIOMBINO DESE, Italy.
Recommended Story: Do Stock Splits Help Investors?
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Stevanato Group right now?
Before you consider Stevanato Group, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Stevanato Group wasn’t on the list.
Although Stevanato Group currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here